Drug Search Results
More Filters [+]

hepatitis B immunoglobulin

Alternative Names: hepatitis B immunoglobulin
Latest Update: 2023-10-10
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: N/A

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intravenous,Intramuscular

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Bulgaria | Canada | China | Colombia | Croatia | Czech | Denmark | Dominican Republic | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Indonesia | Ireland | Israel | Italy | Korea | Latvia | Lebanon | Lithuania | Malta | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Biotest AG
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for hepatitis B immunoglobulin

Countries in Clinic: Germany

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Hepatitis A|Hepatitis B, Chronic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

HBIG

P2

Recruiting

Hepatitis A|Hepatitis B, Chronic

2024-11-01

2021-005362-18

P2

Active, not recruiting

Hepatitis B, Chronic

2023-07-25

Recent News Events